Publicaciones (14) Publicaciones en las que ha participado algún/a investigador/a

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Chemotherapy-free treatments: Are we ready for prime time?

    Annals of Oncology

  3. Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)

    Clinical and Translational Oncology

  4. Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))

    European Urology

  5. Corrigendum: Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis (Annals of Oncology (2012) 23 (1130-1137) DOI: 10.1093/annonc/mdr432)

    Annals of Oncology

  6. Corrigendum: Safety and dose modification for patients receiving niraparib (Annals of Oncology (2018) DOI: 10.1093/annonc/mdy181)

    Annals of Oncology

  7. Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies

    TH Open

  8. Erratum: A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization (Cell (2018) 175(2) (313–326), (S0092867418312479) (10.1016/j.cell.2018.09.035))

    Cell

  9. Erratum: ERRATUM: Early-drug development in the era of immuno-oncology: Are we ready to face the challenges? (Ann Oncol (2018) 29 (1727–1740) DOI: 10.1093/annonc/mdy225)

    Annals of Oncology

  10. Erratum: Early-drug development in the era of immuno-oncology: are we ready to face the challenges? (Annals of oncology : official journal of the European Society for Medical Oncology (2018) 29 8 (1727-1740) PII: S0923-7534(19)60969-5)

    Annals of oncology : official journal of the European Society for Medical Oncology

  11. Erratum: Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience (PLoS ONE (2019)14:6 (e0217881)Doi:10.1371/journal.pone.0217881)

    PLoS ONE

  12. Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection

    Annals of Oncology

  13. Joint ENGOT and GOG Foundation requirements for trials with industry partners

    Gynecologic Oncology

  14. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey